Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a

NCT03320265 is registered in ClinicalTrials.gov with Athera Biotechnologies AB as lead sponsor.

NCT NCT03320265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03320265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a
Lead sponsor
Athera Biotechnologies AB
Phase
Phase 2
Overall status
Terminated
Start date
October 11, 2017
Completion date
July 3, 2018
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

arterial inflammation, cardiovascular diseases